The overexpression of RET was also detected by immunohistochemical methods in 40–65% of samples from pancreatic tumors and 20–75% of samples from prostate cancer as well as in samples from other cancers (reviewed in detail by Mullican, 2019 [24]), and it is generally correlated with worse prognosis and more advanced tumor stages [102,121,122]. This evidence concerns the gene RET and prostate cancer.